Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MPO | P05164 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL647632 | 0.80 | HSD17B10 (0.64) | HSD17B10NAPRTCYP1A2CYP2C19LMNA | |
| SCHEMBL21397880 | 0.78 | HSD17B10 (0.61) | HSD17B10NAPRTCYP1A2CYP2C19LMNA | |
| SCHEMBL28358911 | 0.76 | HSD17B10 (0.59) | HSD17B10NAPRTCYP1A2CYP2C19LMNA | |
| SCHEMBL27791013 | 0.76 | HSD17B10 (0.59) | HSD17B10NAPRTCYP1A2CYP2C19LMNA | |
| SCHEMBL27511341 | 0.76 | HSD17B10 (0.59) | HSD17B10NAPRTCYP1A2CYP2C19LMNA | |
| SCHEMBL1480310 | 0.76 | HSD17B10 (0.59) | HSD17B10NAPRTCYP1A2CYP2C19LMNA | |
| Methyl Isonicotinate SCHEMBL180574 | 0.76 | CYP1A2 (0.60) | HSD17B10NAPRTCYP1A2CYP2C19LMNA | |
| Methyl Isonicotinate SCHEMBL820082 | 0.76 | CYP1A2 (0.60) | HSD17B10NAPRTCYP1A2CYP2C19LMNA | |
| SCHEMBL15972749 | 0.76 | HSD17B10 (0.59) | HSD17B10NAPRTCYP1A2CYP2C19LMNA | |
| SCHEMBL27418916 | 0.76 | HSD17B10 (0.59) | HSD17B10NAPRTCYP1A2CYP2C19LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130005730-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | MEDIVIR AB (SE) | 2013-01-03 | — | — | US | claimed |
| EP-2499120-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | Novadex Pharmaceuticals AB (SE) | 2012-09-19 | — | — | EP | claimed |
| WO-2011056126-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | NOVADEX PHARMACEUTICALS AB (SE) | 2011-05-12 | — | — | WO | claimed |
| EP-1329160-A2 | 4-ACYLAMINOPYRAZOLE DERIVATIVES | Sankyo Company, Limited (JP) | 2003-07-23 | — | — | EP | claimed |
| WO-2023210623-A1 | HALOALKYL SULFONE ANILIDE COMPOUND AND HERBICIDE CONTAINING SAME | 株式会社エス・ディー・エス バイオテック | 2023-11-02 | — | — | WO | disclosed |
| US-20130005730-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | MEDIVIR AB (SE) | 2013-01-03 | — | — | US | disclosed |
| US-20110190296-A1 | Substituted Pyrrole Derivatives and Their Use as HMG-CO Inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2011-08-04 | — | — | US | disclosed |
| US-20110190369-A1 | Substituted Pyrrole Derivatives and Their Use as HMG-CO Inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2011-08-04 | — | — | US | disclosed |
| WO-2011056126-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | NOVADEX PHARMACEUTICALS AB (SE) | 2011-05-12 | — | — | WO | disclosed |
| EP-2319843-A1 | Substituted pyrrole derivatives and their use as HMG-CO inhibitors | Ranbaxy Laboratories Limited (IN) | 2011-05-11 | — | — | EP | disclosed |
| US-7923467-B2 | Substituted pyrrole derivatives and their use as HMG-CO inhibitors | Ranbaxy Laboratories, Inc. (IN) | 2011-04-12 | — | — | US | disclosed |
| US-20100056602-A1 | Substituted Pyrrole Derivatives And Their Use As HMG-CO Inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2010-03-04 | — | — | US | disclosed |
| US-6265418-B1 | ANTICOAGULANTS | UBE INDUSTRIES, LTD. (JP) | 2001-07-24 | — | — | US | disclosed |
| WO-2001005770-A1 | BENZIMIDAZOLONE DERIVATIVES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-01-25 | — | — | WO | disclosed |
| EP-1020467-A1 | N-ACYLAMINO ACID AMIDE COMPOUNDS AND INTERMEDIATES FOR PREPARATION THEREOF | UBE INDUSTRIES LIMITED (JP) | 2000-07-19 | — | — | EP | disclosed |
| EP-0148883-B1 | ALLOPURINOL PRODRUGS | A/S GEA Farmaceutisk Fabrik (DK) | 1990-02-14 | — | — | EP | disclosed |
| US-4694006-A | Acyl- or acyloxymethyl-allopurinol prodrugs | A/S GEA (DK) | 1987-09-15 | — | — | US | disclosed |
| EP-0148883-A1 | ALLOPURINOL PRODRUGS. | GEA AS (DK) | 1985-07-24 | — | — | EP | disclosed |
| WO-1985000368-A1 | ALLOPURINOL PRODRUGS | A/S GEA (DK) | 1985-01-31 | — | — | WO | disclosed |
| US-3965099-A | Cephalosporin esters with antibacterial activity | SMITHKLINE CORPORATION (US) | 1976-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005730-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | REN, AGTR1, ACE | HSD17B10 1199/4885NAPRT 2712/4885CYP1A2 199/4885 |
| US-20100056602-A1 | Substituted Pyrrole Derivatives And Their Use As HMG-CO Inhibitors | HMGCR, HMGB2, HMGB3 | HSD17B10 57/4885NAPRT 1001/4885CYP1A2 546/4885 |
| US-20110190369-A1 | Substituted Pyrrole Derivatives and Their Use as HMG-CO Inhibitors | HMGCR, HMGB2, HMGB3 | HSD17B10 57/4885NAPRT 1001/4885CYP1A2 546/4885 |
| US-20110190296-A1 | Substituted Pyrrole Derivatives and Their Use as HMG-CO Inhibitors | HMGCR, HMGB2, HMGB3 | HSD17B10 57/4885NAPRT 1001/4885CYP1A2 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.